Ketteler T, Krahwinkel W, Wolfertz J, Gödke J, Hoffmeister T, Scheuble L, Gülker H
Wuppertal Heart Center, Department of Cardiology, University of Witten/Herdecke, Germany.
Eur Heart J. 1997 Jun;18 Suppl D:D24-30. doi: 10.1093/eurheartj/18.suppl_d.24.
Arbutamine, a new potent non-selective beta-adrenoceptor agonist with mild alpha 1-sympathomimetic activity, has been developed specifically for pharmacological stress testing. The drug acts like physical exercise, increasing both heart rate and myocardial contractility. Sensitivity, specificity and accuracy in detecting significant stenotic coronary artery disease are 76%, 96%, and 82%, respectively, again similar to those of exercise echocardiography. The drug is delivered by a computerized drug delivery and monitoring device (GenESA) which adjusts the infusion rate according to the patient's heart rate data feedback. The drug is generally well tolerated and has an acceptable safety profile. This article describes recent clinical experience with arbutamine and presents preliminary results of a multicentre multinational study which evaluates the clinical utility and safety of the GenESA system in diagnosing coronary artery disease.
阿巴胺是一种新型强效非选择性β-肾上腺素能受体激动剂，具有轻微的α1-拟交感神经活性，专为药理应激试验而研发。该药的作用类似于体育锻炼，可提高心率和心肌收缩力。检测显著狭窄性冠状动脉疾病的敏感性、特异性和准确性分别为76%、96%和82%，同样与运动超声心动图的结果相似。该药通过计算机化药物输送和监测装置（GenESA）给药，该装置根据患者的心率数据反馈调整输注速率。该药一般耐受性良好，安全性也可接受。本文描述了近期使用阿巴胺的临床经验，并展示了一项多中心多国研究的初步结果，该研究评估了GenESA系统在诊断冠状动脉疾病方面的临床效用和安全性。
